Viewing StudyNCT03056755



Ignite Creation Date: 2024-05-06 @ 9:43 AM
Last Modification Date: 2024-10-26 @ 12:18 PM
Study NCT ID: NCT03056755
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2024-06-20
First Post: 2017-02-15

Brief Title: Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole Based on Prior Endocrine Therapy in Patients With PIK3CA Mutant HR HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments
Sponsor:
Organization: Novartis

Study Design

Study Type: INTERVENTIONAL
Expanded Access Type Individual: None
Expanded Access Type Intermediate: None
Expanded Access Type Treatment: None
Patient Registry: None
Target Duration: None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention: None
Bio Spec Description: None
Enrollment Count: 379
Enrollment Type: ACTUAL
Design Primary Purpose:
Design Masking:
Phases:
Name
PHASE2
Observational Models:
Time Perspective List:
Who Masked List: